23ME-00610 / 23andMe 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  23ME-00610 / 23andMe
    Trial completion date, Trial primary completion date, Tumor mutational burden:  23ME-00610-CLIN-001: A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) -  May 22, 2024   
    P1/2,  N=141, Active, not recruiting, 
    Based on PK/PD, safety, and preliminary anti-tumor activity, 1400 mg Q3W was selected as the dose for further study. Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
  • ||||||||||  23ME-00610 / 23andMe
    New insights into targeting the CD200R1 pathway in T and NK cells using 23ME-00610 as a single agent or in combination (Section 38) -  Mar 5, 2024 - Abstract #AACR2024AACR_3752;    
    P1/2
    Taken together, these data demonstrate that 23ME-00610 can enhance both NK and T cell antitumor effector functions, and 23ME-00610 could synergize with anti-PD-1 to further increase the activity of T cells against cancer cells. The results of this study provide evidence that 23ME-00610 could expand IO treatment options for patients with advanced solid malignancies as a single agent or in combination with other anti-tumor therapeutics.